To view or add a comment, sign in ' Eli Lilly and Company has announced positive topline results from two additional Phase III trials of retatrutide, its investigational first-in-class GIP/GLP-1/glucagon triple receptor agonist for obesity and related metabolic conditions
(2024) 121:e2321972121
The most commonly cited preclinical protocols report 10 g/kg in published rat studies of tendon/ligament healing
Additionally, its detoxifying prowess further solidifies its application in various health and wellness products, aiding in the elimination of harmful toxins from the body
YC Fan et al., "The Utilization of Glucagon-like Peptide 1 Agonists and Risk of Following External Eye Diseases in Type 2 Diabetes Mellitus Individuals: A Population-Based Study," Healthcare (Basel), 11, 2749 (2023)
The figure printed on each batch's Certificate of Analysis is the actual value recorded in the laboratory for that batch, not a generic marketing claim